Is treatment of insulin resistance beneficial independent of glycemia?

The clinical definition of the Insulin Resistance or Metabolic Syndrome is shown in Table 1. Subjects who fulfill these criteria are at increased risk for cardiovascular disease (CVD). The criteria of the National Cholesterol Education Program are more clinically relevant because those measurements are readily available. Although those with impaired fasting glucose and/or impaired glucose tolerance (IGT) are at increased risk for the subsequent development of type 2 diabetes (3), abnormal glycemia is not an independent predictor of cardiovascular disease once the other risk factors are taken into account (4,5). Three recent randomized, controlled studies have shown that lifestyle intervention with diet and exercise can decrease the development of type 2 diabetes in subjects with IGT (6–8). However, although exercise is associated with less CVD (9), the hypothesis that exercise decreases CVD has never been directly tested in a randomized, controlled clinical trial. Insulin resistance, highly associated with visceral fat accumulation (10), characterizes the Insulin Resistance or Metabolic Syndrome. Furthermore, measured insulin resistance predicts CVD (11). In this issue of Diabetes Care , Shadid and Jenson (12) compare the effects of diet and exercise versus pioglitazone in insulin-resistant nondiabetic men and premenopausal women with upper body obesity (i.e. visceral fat accumulation). Insulin sensitivity increased in both groups. Those given diet and exercise showed weight loss and decreased visceral, subcutaneous, total body, and leg fat, whereas the subjects prescribed …

[1]  Erik Jørgensen,et al.  Low restenosis rate of the NIR coronary stent: results of the Danish multicenter stent study (DANSTENT)--a randomized trial comparing a first-generation stent with a second-generation stent. , 2003, American heart journal.

[2]  K. Tanabe,et al.  Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. , 2003, American heart journal.

[3]  D. Simonson,et al.  Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. , 2003, Diabetes care.

[4]  J. Shaw,et al.  The prevention of type 2 diabetes--lifestyle change or pharmacotherapy? A challenge for the 21st century. , 2003, Diabetes research and clinical practice.

[5]  M. Jensen,et al.  Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. , 2003, Diabetes care.

[6]  G. Reaven,et al.  Insulin resistance as a predictor of age-related diseases. , 2001, The Journal of clinical endocrinology and metabolism.

[7]  S. Aronoff,et al.  Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.

[8]  T. Shoji,et al.  Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in patients with type 2 diabetes. Vessel wall properties in type 2 diabetes. , 1999, Diabetes care.

[9]  A. Aljada,et al.  Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? , 2001, The Journal of clinical endocrinology and metabolism.

[10]  W. Koenig,et al.  Antidiabetic PPAR&ggr;-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease , 2003 .

[11]  A. Aljada,et al.  Nuclear Factor-κB Suppressive and Inhibitor-κB Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action?1 , 2001 .

[12]  S. Haffner,et al.  Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.

[13]  W. März,et al.  Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. , 2003, Diabetes care.

[14]  M. Hanefeld,et al.  Rosiglitazone Improves Postprandial Glycemia and Markers of Endothelial Function in Patients with Type 2 Diabetes , 2002 .

[15]  A. Aljada,et al.  Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. , 2001, The Journal of clinical endocrinology and metabolism.

[16]  F. Logerfo,et al.  The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. , 2003, Metabolism: clinical and experimental.

[17]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[18]  L. Fink,et al.  Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. , 1998, Journal of diabetes and its complications.

[19]  Aldons J. Lusis,et al.  Atherosclerosis : Vascular biology , 2000 .

[20]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[21]  W. Koenig,et al.  Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[22]  H. Lebovitz,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes , 1999 .

[23]  H. Koshiyama,et al.  Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.

[24]  J. Brunzell,et al.  Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. , 2002, The American journal of cardiology.

[25]  S. O’Rahilly,et al.  The perils of portliness: causes and consequences of visceral adiposity. , 2000, Diabetes.

[26]  K. Nakao,et al.  Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. , 2003, Diabetes care.

[27]  C. Tack,et al.  Troglitazone Decreases the Proportion of Small, Dense LDL and Increases the Resistance of LDL to Oxidation in Obese Subjects , 1998, Diabetes Care.

[28]  J. Cohn Vascular wall function as a risk marker for cardiovascular disease. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[29]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[30]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[31]  V. Fonseca,et al.  Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. , 1998, The Journal of clinical endocrinology and metabolism.

[32]  Ralph B D'Agostino,et al.  Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. , 2002, Diabetes care.

[33]  S. Anderson,et al.  Aortic Pulse-Wave Velocity and Its Relationship to Mortality in Diabetes and Glucose Intolerance: An Integrated Index of Vascular Function? , 2002, Circulation.

[34]  S. Tanaka,et al.  Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. , 1998, The Journal of clinical endocrinology and metabolism.

[35]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[36]  Fernando Costa,et al.  Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Ph , 2003, Circulation.

[37]  S. Haffner,et al.  Predicting future cardiovascular disease: do we need the oral glucose tolerance test? , 2002, Diabetes care.

[38]  E. Ferrannini,et al.  Troglitazone Reduces LDL Oxidation and Lowers Plasma E-selectin Concentration in NIDDM Patients , 1998, Diabetes.

[39]  J. Toole,et al.  Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.